Discover
TCRX
TScan Therapeutics, Inc.
1.07
2 x 0.75
2 x 1.27
bid
ask
+
0.09
9.17%
2 @ 04:00 PM
1.07 +0.00 (0.00%)
| Ytd | 7.00% | |
| 1y | -25.17% |
0.98
day range
1.08
0.82
52 week range
2.57
| Open | 0.99 | Prev Close | 0.98 | Low | 0.98 | High | 1.08 | Mkt Cap | 69.93M |
| Vol | 1.68M | Avg Vol | 886.23K | EPS | -0.96 | P/E | N/A | Forward P/E | -2.33 |
| Beta | 0.78 | Short Ratio | 9.02 | Inst. Own | 86.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 1.06 | 200-d Avg | 1.23 | 1yr Est | 12.14 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.28 | -0.25 | 0.03 | 10.71% |
| 2024-08-12 | 2024-06 | -0.3 | N/A | N/A | N/A |
| 2024-08-12 | 2024-06 | -0.3 | -0.28 | 0.02 | 6.67% |
| 2024-05-13 | 2024-03 | -0.25 | -0.32 | -0.07 | -28.00% |
| 2024-05-13 | 2024-03 | -0.25 | N/A | N/A | N/A |
| 2024-03-06 | 2023-12 | -0.3 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-12-11 | Needham | Upgrade | Buy | Buy |
| 2024-11-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-12 | Needham | Upgrade | Buy | Buy |
| 2024-11-06 | Needham | Upgrade | Buy | Buy |
| 2024-08-13 | Wedbush | Upgrade | Outperform | Outperform |
Profile
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-12-18 | BARBERICH TIMOTHY JOSEPH | Director | 100.29K | Purchase |
| 2024-09-22 | KLENCKE BARBARA M.D. | Director | 70.00K | Purchase |
| 2024-12-12 | LYNX1 CAPITAL MANAGEMENT LP | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2022-12-27 | SILVER BRIAN M. | Chief Financial Officer | 32.89K | Purchase |
| 2024-08-22 | ZDRAVESKI ZORAN | Officer | 4.72K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Lynx1 Capital Management Lp | 5.22M | 15.73M | 10.64% |
| 2024-09-29 | EcoR1 Capital, LLC | 5.00M | 15.05M | 10.18% |
| 2024-09-29 | Blackrock Inc. | 4.63M | 13.94M | 9.44% |
| 2024-09-29 | Adage Capital Partners GP L.L.C. | 4.40M | 13.24M | 8.96% |
| 2024-09-29 | BVF Inc. | 2.99M | 9.00M | 6.09% |
| 2024-09-29 | Baker Bros. Advisors, LP | 2.78M | 8.38M | 5.67% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.37M | 4.12M | 2.79% |
| 2024-09-29 | Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF | 1.05M | 3.15M | 2.13% |
| 2024-09-29 | BlackRock Health Sciences Term Trust | 1.05M | 3.15M | 2.13% |
| 2024-10-30 | iShares Russell 2000 ETF | 967.48K | 2.91M | 1.97% |
| 2024-08-30 | Blackrock Funds-Health Sciences Opportunity Portfolio | 681.02K | 2.05M | 1.39% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 645.51K | 1.94M | 1.31% |